The mts1/S100A4 gene has been isolated as a gene specifically expressed in murine and human metastatic tumor cells (1) Expression of mts1 in nonmetastatic murine and human cell lines results in a more malignant phenotype (2).
S100 proteins in a large group of cellular events such as neurite growth, cell-cell communication, cell growth, cell structure, energy metabolism, contraction, motility, intracellular signaling and cell division (3) .
Mts1 participates in the regulation of cytoskeletal dynamics and cell motility by association with stress fibers, F-actin and tropomyosin (4, 5) . In our laboratory the heavy chain of nonmuscle myosin II (MHC) was identified as a target for Mts1 (6) . The Mts1-MHC interaction results in the inhibition of the protein kinase C (PKC) -mediated phosphorylation of the MHC molecule and associates Mts1 with cell motility, which is one of the determinative functions in the metastatic disease (7) .
Tumor suppressor p53 protein is a transcriptional factor, which regulates several cellular processes creating limitations for tumorigenic transformation. In response to "proliferation affecting" events (DNA damage, oncogenes, oxidative stress, etc), cells utilizing p53 pathways may switch to either growth arrest, programmed cell death or cell differentiation (8) . The pathways of p53 regulation are only starting to emerge.
As a transcriptional regulator p53 modulates the expression of target genes by binding to specific p53-responsive sites. The majority of genes regulated by p53 are involved either in cell cycle control or apoptosis.
The p53 protein has three main functional domains. The N-terminal transactivation domain interacts with several components of the basal transcription machinery and provides a transcriptional regulation (9) . The central part of the protein contains the specific DNAbinding domain, a hotspot for p53 mutations that affect its DNA -binding ability and lead to tumorigenic transformation of cells. The C-terminal part of p53 is a multifunctional domain, responsible for oligomerization, nuclear translocation, and binding to damaged DNA. In addition, the C-terminus negatively regulates the specific DNA binding activity of the core domain. Binding to certain proteins, acetylation, or phosphorylation by PKC and casein kinase II (CKII) abolish the negative effect imposed by the C-terminus. The C-terminus regulates the conversion of p53 from inactive to active forms and vise versa, thereby modulating the transcriptional activity of p53 (10) (11) .
Here we show a physical link between Mts1 and amino acid residues 360-393 of the Cterminal domain of p53. This interaction affects the phosphorylation of p53 by PKC as well as its DNA-binding capacity in vitro. Moreover, Mts1 influences the transactivation of a reporter gene placed under the control of p53-binding elements in vivo and differentially modulates the transcription of p53 -regulated genes. Co-operation between wild type p53 and Mts1 may induce an apoptotic response depending on environment and cell type.
EXPERIMENTAL PROCEDURES

Plasmids
The coding region of mts1 was cloned into pSK3 (Pharmacia AS, Copenhagen, Denmark) vector giving a construct pSV-mts1. pSVBcl2 was constructed by cloning the Bcl2 /XhoI insert from PEBS7-425 (gift of Dr. M. Jäättelä) into the pSK3 vector. The following mouse wild type p53 PCR products were designed: #1 -full size coding region (390 aa) was amplified using the primers: forward -CGGGATCC GACTGGATGACTGCCATGGA (Qiagen, GmbH, Hilden, Germany). pSP65m65 plasmid DNA (gift of Dr. J. Skouv) was used for the amplification of mouse p53 and its domains. pC53-SN3 (human wild type p53) and pC53-SCX3 (human mutant p53 ,143 val →ala) eukariotic expression plasmids were gifts of Dr. J. Skouv. For cloning into the tet-inducible, conventional expression system, mts1 cDNA was excised, cloned into pUHD 10-3 and used for transfection of cell lines producing reverse tetracycline-controlled transactivator (pUHD172-neo) (Clontech Laboratories GmbH, Heidelberg, Germany). p21 -luc was constructed by cloning 13 copies of the p53 binding consensus element from the p21/WAF promoter, excised from pSK45-13-2 (provided by Dr.B.Vogelstein) into the pfLuc reporter construct containing the Photinus pyralis luciferase gene under the minimal c-fos promoter. For Bax-luc construction 5' TCG ACA ATA TAG CCC ACG CCC AGG CTT GTC TC 3' and 3' G TCC GAA CAG AGA TTG AAC ACT CTA G 5' oligonucleotides were annealed and the ends of double stranded DNA were extended with Escherichia coli DNA polymerase I Klenow fragment. Four copies of head-to-tail orientated fragments were cloned into the Hind III site of the pfLuc vector.
The β-galactosidase expression plasmid (pCMV-β-gal) was purchased from Clontech.
pBabe-Hyg contains the Hygromicin-resistance gene and was a gift of Dr. J. Lukas.
The pQE30 expression vector, producing recombinant Mts1-His (7) plasmids encoding human wild type and mutant p53 proteins fused with the GST protein, GST-p53 and GSTp53∆30 (12) were used.
Cell lines transfection
Cells were transfected by electroporation: 1-3x10 6 cells in 100 µl of phosphate saline buffer were transferred into electroporation cuvette and single pulse of 250V and 250µFd was applied using Bio-Rad electroporation system. Clones were selected in the presence of 400µg of G-418. For the conventional clones double selection with G-418 and 200µg/ml Hygromycin was used. In the transient transfection experiments the efficiency of each transfection was monitored by use of co-transfection with a β-galactosidase expression vector, pCMV-β-gal. At 24-48 hours post-transfection, cells were lysed and the luciferase activity was measured using a luminometer (Promega, Madison, WI). Same lysates were tested for β-galactosidase activity by using o-nitrophenyl-β-galactopyranoside (Sigma, St.Louis, Missouri) as a chromogenic substrate (13) .
Immunofluoresence analysis
Cells were grown on 10mm glasses and fixed with freshly prepared 4% paraformaldehyde in PBS 30 min on ice. 0.2% Triton X-100 was used to permeabilize the cells. Primary and secondary antibody were applied in DME culture medium with 10% FCS, either for 1 hour at room temperature. The antibodies used: rabbit anti-mouse Mts1 affinity purified (1:500) and FITC-conjugated goat anti-rabbit IgG 1:100 (Zymed).
To evaluate the efficiency of transfection, the cells grown on one of the glasses were fixed with 0.5% glutaraldehyde in PBS for 5 min, washed 3 times with PBS and incubated with X-gal staining solution, 1mg/ml X-gal (5-bromo-4-chloro-3 indolyl β-Dgalactopyranoside), 35 mM potassium ferricyanide, 35 mM potassium ferrocyanide and 2mM MgCl 2 in PBS.
Preparation of recombinant proteins
Histidine -tagged p53 and Mts1 proteins were expressed in XL-blue E. coli by induction with 0.2 mM isopropyl ²D-thiogalactopyranoside for 4 hours at 37°C. Protein isolation in denaturing conditions and the following renaturation were performed according the manufacturers protocol (Qiagen GmbH, Hilden, Germany).
Western blotting
Protein isolation and Western blotting were performed as described (6) . Immunostaining and protein band visualization with ECL system SuperSignal ® (Pierce, Rockford, Il) was carried out according to the manufacturer's protocol.
Far Western (blot overlay)
Proteins were separated by SDS-PAGE and blotted to Immobilon-P (Millipore, Bedford, MA). After blotting the membranes were pre-incubated in the blocking buffer: 0.2M NaCl, 50 mM Tris HCl pH 7.5, 3% BSA, 0.1% PEG 8000 for 2h at room temperature. Overlay with 1 µg/ml of recombinant Mts1 protein was performed for 20 min at room temperature in 0.2M NaCl, 50 mM Tris pH 7.5, 12 mM β-Mercaptoethanol, 0.1% BSA, 1% PEG 8000 and 1mM CaCl 2 . After three washings the membranes were immunoprobed with anti-Mts1 antibodies by standard Western blotting procedure.
Immunoprecipitation and in vitro pull-down assays
Cells were metabolically labeled for 4h in methionine-and cysteine-free medium Gels were fixed in 5% trichloroacetic acid, dried and exposed to Kodak X-ray film. To quantify the intensity of the protein bands, a Molecular Dynamics computing densitometry (Sunnyvale, CA) with ImageQuant software was used.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as previously described (13) . To perform EMSA, nuclear extracts were incubated with end-labeled oligonucleotides that contained binding sites for p53 or Oct-1 proteins. Oligonucleotide sequences were as follows: for Oct-1 -TGCGAATGCAAATCACTAGAA ; for p53 -GAACATGTCCCAACATGTTG, derived from the promoter of p21/WAF . The reactions were carried out in 10µl of the buffer containing 100 mM KCl, 1 mM MgCl 2 , 1 mM DTT, 0.1% NP-40, 0.5 mg/ml BSA, 5% glycerol. To perform the gel supershift analysis, anti-p53 antibody pAb421 was added to the EMSA reaction mixtures. The incubation with antibody was carried out for 1 h at 4°C after the binding reaction was completed.
Northern blot analysis CSML-0 conventional Mts1-tet-inducible cells were grown at low and dense conditions and induced with 2µg/ml Doxycyline for 0, 24, 48 and 72h. RNA was isolated as described (14) . Gel electrophoresis and Northern blot analyses were performed as described (15) . The same filter was sequentially hybridized with murine p21/WAF, Bax, Cyclin G1 and thrombospondin-1 (THBS1) probes. The amounts of mRNA on the filters were calibrated by hybridization with γ-32 P-ATP-labeled poly (U) probe. To quantify the intensities of the bands membranes were scanned using a Molecular Dynamics computing densitometer (Sunnyvale, CA) with ImageQuant software.
RESULTS
Co-expression of Mts1 and wt-p53 leads to cell-specific apoptosis
Plasmid DNAs encoding mts1 and neomycin resistance were transfected into Mts1-negative CSML-0 and VMR-liv cells. Fig.1 shows that the clonal survival of the transfected cells evaluated after three weeks was four times lower compared to the mock-transfected ones (vector DNA). To investigate the cause of low clonal survival anti-apoptotic Bcl2 cDNAs, in sense and antisense orientations, were co-transfected. The data revealed that expression of the active (sense) Bcl2 acted as a rescue factor and increased the relative clonal survival up to control level, whereas the non-active (antisense) did not. Taken together, these results suggest that Mts1 expression induces programmed cell death, which could be prevented by Bcl2 expression.
Further experiments were designed to study the mechanism of the mts1-induced apoptosis.
Since p53 is a key trigger of apoptosis, we addressed the question whether Mts1-induced apoptosis is dependent on functional p53. We analyzed the expression of Mts1 in a number of human and mouse tumor cell lines of various origins and in immortalized mouse fibroblasts with known p53 status. The data summarized in Table 1 show that all 7 tumor cell lines homozygous for wild type p53 displayed a Mts1-negative phenotype, while 16 protein encoded by pC53-SCX3 is unable to bind DNA and to act as a transcriptional regulator. Moreover, it exhibits a dominant-negative effect and inhibits the activity of coexisting wt-p53 (17) . The number of clones was estimated three weeks after transfection.
The results presented in Fig. 2 demonstrate that the lowest clonal survival was seen when both Mts1 and wt-p53 were coexpressed (compare Saos-2 -bars 2, 4 and CSML-0 bars 1, 4). In CSML-0, which harbors wt-p53, the clonal survival was 5 times lower in mts1-transfectants (bar1) than in the control transfection (bar 6). In Saos-2 cells where p53 is deleted, the survival of the mts1-transfected clones (bar 1) was comparable to the control transfection (bar 6). The transfection of mt-p53 did not affect clonal survival (bars 3 and 5), as well as transfection with the vector DNA (bar 6) in both cell lines.
To obtain more direct evidence of p53-dependent Mts1-induced apoptosis, we used two As an alternative approach we took advantage of stable clones expressing tet-inducible Mts1,which were derived from Mts1-negative Saos-2#1109 and CSML-0 cells. Upon transient transfection of wt-p53 in Saos-2#1109 expressing Mts1 (+Dox) (Fig.3B, panel c) , cells bearing features of apoptosis were detected by DAPI staining 24 h post-transfection (Fig. 3B, panel a) . mt-p53 did not initiate cell death program in Mts1-induced cells (data not shown). Parameters concerning cell transfection efficiency and apoptotic hallmarks 15 h after transfection are illustrated in the Table 2 . After wt-p53 transfection in Saos-2#1109 cells the number of nuclei with fragmented chromatin was three times higher in the presence of Mts1 expression (+Dox), than in its absence (÷Dox), reaching 15.6% and 5.1%, respectively (Fig.   3B, panel b and d) . Similarly, 3 to 4 times higher number of apoptotic cells was detected upon tet-induced Mts1 expression in CSML-0 cells, as verified by TUNEL staining 24 hours after transfection with wt-p53 (Fig. 3C) . Taken together, these data suggest that Mts1 cooperates with p53 in triggering apoptosis.
Mts1 physically interacts with p53
Next, we studied whether Mts1 co-operates directly with p53 via protein-protein interaction.
To answer this question, we used immunoprecipitation (IP) and Far Western blot analysis.
Lysates from 35 S-metabolically-labeled CSML-100 (mt-p53 and Mts1-positive) and CSML-0 (wt-p53 and Mts1-negative) cells were used for IP with anti-p53 and anti-Mts1 antibodies. As shown in Fig.4A , an 11 kDa protein band corresponding to Mts1 was detected in anti-p53 immunoprecipitates from CSML-100, but not from CSML-0 cells. Conversely, a protein corresponding to p53 in anti-Mts1 immunoprecipitates was co-precipitated from CSML-100 cell lysate. A protein band corresponding to MHC, a known Mts1 target (7), was detected in anti-Mts1 immunoprecipitates but not in anti-p53 and control immunoprecipitates. This confirms that the anti-Mts1 antibodies used are able to coprecipitate Mts1 together with its target proteins. The amount of the Mts1 protein coimmunoprecipitated using anti-p53 antibody was lower than that of p53 in anti-p53
precipitates. This might indicate that only a minor portion of Mts1 is engaged in the interaction with p53. Additionally, the specific radioactive activity per molecule of p53 is three times higher than that of Mts1.
To identify the region of p53, which interacts with Mts1, recombinant p53 peptides corresponding to the N-terminal (#2) aa 1-106, the core (#3) aa 104-288 and the C-terminal (#4) aa 289-390 of murine p53 were obtained. Full length p53 (#1) and the domain peptides were incubated with recombinant Mts1 protein and precipitated with anti-p53 antibodies followed by Western blot analysis using anti-Mts1 antibodies. As shown in 4) . As a positive control we used a recombinant fragment of non-muscle myosin, which is known to be Mts1 target (Fig. 4C, lane 5) . Coomassie Blue stained gel, run in parallel, was used to verify the quantities of the proteins.
For more precise mapping of the Mts1 binding site on the C-terminal domain of p53, fulllength GST-wt-p53 and GST-p53∆30, lacking the last 30 C-terminal residues were used.
The p53 fusion proteins as well as the GST protein alone were incubated with recombinant Mts1. The complexes were immobilized on Glutathione -Sepharose 4B beads. The Mts1 protein bound to p53 was analyzed by SDS-PAGE followed by Western blot analysis using anti-Mts1 antibodies. The data shown in Fig.4D demonstrate that Mts1 binds GST-p53∆30 with much lower efficiency than to full-length p53. This indicates the importance of residues 364-393 of the C-terminal domain for the p53-Mts1 interaction.
Thus, our results taken together demonstrate a direct interaction between Mts1 and the Cterminal domain of p53.
The Mts1 protein inhibits phosphorylation of p53 by PKC
We showed previously that Mts1 interacts with MHC and inhibits the phosphorylation of myosin by PKC (7). Since the Mts1-binding site of p53 harbors both PKC and CKII phosphorylation sites, we investigated whether Mts1 affects p53 phosphorylation.
Recombinant full-length p53 (#1) and its domain peptides (# 2, 3, and 4) were phosphorylated by PKC in the absence or presence of recombinant Mts1 and analyzed by SDS-PAGE. The data obtained in three independent experiments indicate a reliable 37% (SD± 2.6%) inhibition of the PKC-mediated phosphorylation of full-length p53 protein, and 56% (SD±8.1%) of its C-terminal fragment by Mts1 (Fig. 5A ). Since Mts1 did not affect the phosphorylation of the N-terminal and DNA-binding domains of p53 as well as PKC autophosphorylation at the same conditions, we exclude the possibility that the recombinant Mts1 protein acts as a competitive substrate. Interestingly, no inhibition/activation of CKII mediated phosphorylation of full-length p53, or the C-terminal domain, was observed in the presence of Mts1 (Fig. 5B ).
In conclusion, our results revealed that Mts1 specifically inhibits the phosphorylation of the C-terminal domain of p53 by PKC in vitro.
Modulation of p53 DNA-binding activity by Mts1
To assess the functional significance of the Mts1-p53 interaction, we investigated whether 15) . These experiments demonstrate that Mts1 is able to modulate the DNA-binding capacity of p53.
Mts1 affects p53 -dependent transcription
The results presented above suggest that Mts1 might be involved in the modulation of p53- (18, 19) . Although the status of p53 in these tumor samples was not tested directly, the positive immunohistostaining indicates that p53 is likely mutated since the level of wt-p53 in most cells and tissues is at or below the level of detection in paraffinimbedded samples. Though the association between p53 overexpression and the presence of Mts1 in above mentioned studies is not so striking compared to our data, it is nevertheless points to the similar conclusion.
Co-existence of wt-p53 and Mts1 in immortalized fibroblasts, probably, might be explained by conformational transformation of p53 as it was observed in the 10T½ cell line (16) . The co-expression of Mts1 and elevated level of wt-p53 was shown in a dexamethasoneinducible clone of B16 melanoma cell line transfected with MMTV-mts1 (20) . We assume that there may be more than one interpretation of these data. This could be due to functional inactivation of p53 by glucocoticoid receptor (GR), since it was shown that GR forms a complex with p53 in vivo, resulting in cytoplasmic sequestration of both p53 and GR (21).
Alternatively, dexamethasone-mediated pleiotrophic effect on gene regulation, cell cycle, apoptosis etc. in GR -positive cells might neutralize p53/Mts1 cooperation.
The most prominent biological effects elicited by p53 as a transcriptional activator are cell cycle arrest and apoptosis in response to diverse types of stress (22) . A number of proteins that interact with p53 and modulate its functional activity by covalent and noncovalent modifications have been identified (9, 8) . The C-terminal basic domain of p53 was shown to negatively regulate the specific DNA binding activity of the protein (9). Modulators of p53, which bind or modify this region, dramatically affect the activity of the protein. Interaction with the C-terminal -specific antibody pAb421, single-stranded RNA and DNA (23) and deletion of this regulatory domain (24) abolish the negative regulatory role of the Cterminus thus activating p53 (9) . Additionally, phosphorylation of 392 Ser by CKII or 371 Ser , 376 Ser , and 378 Ser by PKC results in protein activation (25) . Therefore, it is logical that Mts1, which according to our data interacts with the C-terminal regulatory domain, is able to modulate p53 activity.
Using several approaches, we have demonstrated a physical interaction between p53 and Mts1. The Mts1-binding site is localized in the C-terminus of the p53 molecule, including aa 364-393. The interaction of Mts1 with p53 results in inhibition of p53 phosphorylation by PKC, but not by CKII. Moreover, binding of Mts1 to p53 leads to the inhibition of the complex formation between p53 and a p53-specific consensus oligonucleotide derived from the p21/WAF promoter. The interaction of p53 with another member of the S100-family, S100B, was shown previously. S100B physically interacts with the C-terminal domain of p53, inhibits its phosphorylation by PKC and influence p53 oligomerization and biological activity (26) . However, a direct influence on the p53 transactivation activity is demonstrated only for Mts1 so far. Recently it was shown using NMR spectroscopy that a peptide from the C-terminal domain of p53 (aa 367-388) does not have a regular structure in its native form.
Binding of S100B in the presence of Ca 2+ leads to conformational alterations of the p53-derived peptide. Three-dimensional structure of the complex reveals several hydrophobic and electrostatic interactions between S100B and p53, which result in a sterical block by S100B on the phosphorylation and acetylation sites on p53 (27) . Such modifications can in turn alter the transcriptional activation capacity of p53 (induction and repression). It is conceivable that Mts1, similarly to S100B, can induce conformational changes in p53.
However, this issue requires further elucidation.
Here we demonstrate that via interaction with p53, Mts1 differentially modulates the transactivation function of p53. Interestingly, the effect of Mts1 on p53 is dependent on the 32,6%
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